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Summary
Objective: Aggrecan degradation by aggrecanases [a disintegrin and metalloproteinase with thrombospondin-like motifs (ADAMTS) 1, 4, 5, 8,
9, 15] is considered to initiate much of the cartilage pathology seen in human arthritis, however, the proteinase responsible and its mode of
control is unclear. The present work was done to examine mechanisms of aggrecanase control in a novel murine epiphyseal cell system and
to determine whether ADAMTS5 alone is responsible for aggrecanolysis by these cells.
Methods: Epiphyseal cells from 4-day-old mice (wild type, TS-5 (/), CD44(/), syndecan-1(/), membrane type-4 matrix metalloprotei-
nase [MT4MMP(/)]) were maintained in non-adherent aggregate cultures and aggrecanolysis studied by biochemical and histochemical
methods. Confocal immunolocalization analyses were done with speciﬁc probes for ADAMTS5, hyaluronan (HA) and aggrecanase-generated
fragments of aggrecan.
Results: Aggrecanolysis by these cells was speciﬁcally aggrecanase-mediated and it occurred spontaneously without the need for addition of
catabolic stimulators. Chondrocytes from ADAMTS5-null mice were aggrecanase-inactive whereas all other mutant cells behaved as wild type
in this regard suggesting that ADAMTS5 activity is not controlled by CD44, syndecan-1 or MT4MMP in this system. Immunohistochemical
analysis supported the central role for ADAMTS5 in the degradative pathway and indicated that aggrecanolysis occurs primarily in the HA-
poor pericellular region in these cultures.
Conclusion: These ﬁndings are consistent with published in vivo studies showing that single-gene ADAMTS5 ablation confers signiﬁcant pro-
tection on cartilage in murine arthritis. We propose that this culture system and the analytical approaches described provide a valuable frame-
work to further delineate the expression, activity and control of ADAMTS-mediated aggrecanolysis in human arthritis.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Abbreviations: ADAMTS a disintegrin and metalloproteinase with thrombospondin-like motifs, HA hyaluronan, HABP hyaluronan binding pro-
tein, G1, G2, G3 globular domains of aggrecan, CS chondroitin sulfate, S-GAG sulfated glycosaminoglycans, MT4MMP membrane type-4
matrix metalloproteinase (MMP17), LPS lipopolysaccharide, OSM oncostatin M, FnF ﬁbronectin fragments.Introduction
Articular chondrocytes are specialized cells responsible for
the synthesis and turnover of cartilage matrix. This matrix
consists primarily of a collagen network, which is held under
tension through the osmotic properties of the entrapped
polyanionic aggrecan. During physiological homeostasis
of cartilage, the aggrecan composition appears to be main-
tained by biosynthetic replacement of molecules under-
going slow proteolysis by aggrecanases, m-calpain and
matrix metalloproteinases (MMPs)1,2. By contrast, in ar-
thritic diseases, aggrecanolysis is accelerated and the ma-
jor sulfated glycosaminoglycans (S-GAG)-bearing products
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2005.39released to synovial ﬂuid result from aggrecanase-mediated
cleavage in the interglobular domain of aggrecan between
Glu392 and Ala393a (Refs. 3,4). In 1999, the aggrecanase
activity present in bovine articular cartilage5 was shown to
be a member of the ADAMTS (a disintegrin and metallopro-
teinase with thrombospondin-like motifs) family of pro-
teases6. Since that time, a considerable body of published
work has described expression, activities and substrate
speciﬁcities of those members of the ADAMTS family (i.e.
1, 4, 5, 8, 9 and 15) that exhibit greater or lesser degrees
of aggrecanase activity.
Past attempts to identify the family member(s) responsible
for human arthritic change have been largely based on
aThe numbering scheme adopted in this paper is taken directly
from the mouse aggrecan sequence provided in the NCBI database
Accession No. A55182. There has been no correction for the 19
residue leader sequence previously applied to aggrecan residue
numbering.2
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ine7, canine8, bovine9, porcine10,11 and human cartilage12.
For example, in bovine explants treated with interleukin 1
(IL-1)13, and explants of cartilage obtained at joint replace-
ment for advanced osteoarthritis14, the available data are
consistent with a primary requirement for ADAMTS4 in car-
tilage aggrecanolysis. Indeed, studies with a human chon-
drosarcoma cell line15,16 and bovine explants13 have
implicated ADAMTS4, syndecan-1 and GPI-anchored mem-
brane type-4 matrix metalloproteinase (MT4MMP) in this
process. On the other hand, attention has been recently fo-
cused on ADAMTS9 as an important activity in human chon-
drocytes17,18. Most recently, in vivo studies with genetically
modiﬁed mice19,20 have implicated ADAMTS5 as the prima-
ry, and perhaps only, active aggrecanase in both post-injury
and inﬂammatory murine arthritis models. Mice lacking func-
tional ADAMTS5 were largely insensitive to the arthritic stim-
uli in these models, whereas deletion of either ADAMTS-1 or
-4 activity conferred no obvious protective effect21,22. It has
become clear that the use of murine transgenic and gene de-
letionmethods has openedmany new opportunities to deﬁne
the network of molecular and cell biological components that
determine aggrecanolysis under both normal and pathologi-
cal conditions in the human joint. We present here a murine
chondrocyte culture system which stably supports the chon-
drocytic phenotype23,24 and which is amenable to genetic,
biochemical and immunohistochemical analyses of aggre-
can turnover.Most interestingly, aggrecanolysis in thismodel
does not require stimulation by exogenous catabolic stimula-
tors and appears to be entirely dependent on ADAMTS5 ac-
tivity, consistent with the recent ﬁndings19,20. This epiphyseal
model represents an ideal vehicle to investigate the path-
ways that regulate ADAMTS5 expression and activity, and
test the efﬁcacy of putative antagonists against this protease.
Method
CHEMICALS AND ANTIBODIES
Collagenase type 2 was from Worthington. Trypsin/
EDTA, Opti-MEM, fetal bovine serum and Ham’s F12 media
were from Invitrogen. Forty microliter ﬁlters were from BD
Biosciences. Hydrogel-coated, non-adherent culture dishes
were from Corning Costar. L-ascorbic acid phosphate was
from Wako Pure Chemicals. AlexaFluor568-conjugated
anti-rabbit IgG, AlexaFluor488-streptavidin and TOTO-3
were from Molecular Probes. HistoGel was from Richard-Al-
lan Scientiﬁc. EZ-link Sulfo-NHS-LC-Biotin kit was from
Pierce Biotechnology Inc. All other histology supplies
were obtained as described25. Afﬁnity-puriﬁed IgGs were
JSCVMA15 (anti-ADAMTS4), JSCKNG26 (anti-ADAMTS5),
anti-NITEGE392 (JSCNIT, anti-NIT), anti-TASELE1298 (JS
CTAS, anti-TAS), anti-G1 and anti-G3 (JSCDGH, LEC-7),
all of which have been previously characterized as speciﬁc
for proteins of deﬁned size on Western blots1,15,26e28.
Some of these reagents have been developed in collabora-
tion between JDS and Afﬁnity Bioreagents, Boulder, CO. All
antibodies were puriﬁed on peptide afﬁnity columns (Sulfo-
link, Pierce Inc.) and were analyzed by SDS-PAGE for IgG
concentration relative to a rabbit IgG standard.
PREPARATION AND CULTURE OF MURINE CHONDROCYTES
Wild-type C57BL/6J mice were purchased from Jackson
laboratories. The generation of mice lacking ADAMTS520,
syndecan-129 and CD4430 have been described. All animal
experimentation was carried out with prior IACUC approvaland under NIH guidelines for the care and use of laboratory
animals. Epiphyseal cartilage (not including growth plate)
was collected from the proximal tibial, distal femoral and
proximal humeral epiphyses of 4-day-old mice. Pooled
epiphyses were brieﬂy rinsed in HBS, placed in an Erlen-
meyer ﬂask in a shaking incubator rotating at 180 rpm and
digested sequentially with trypsin/EDTA [0.05% in phos-
phate buffer saline (PBS)] for 1 h at 37(C, followed by over-
night digestion in collagenase type 2 (0.15% in Opti-MEM,
supplemented with 2% fetal bovine serum). Cells were sep-
arated from debris by ﬁltration through 40 mm ﬁlters and pel-
leted by centrifugation at 290 rcf for 10 min. Pellets were
washed twice by suspension in 20 ml Ham’s F12 medium.
Cells were ﬁnally suspended in Opti-MEM (5 105 cells/ml)
and 1 ml added per 20 mm hydrogel-coated dish as de-
scribed23,24. About 15 cultures were established from a typi-
cal litter of 6 mice. Unless otherwise noted, media were
replaced every 3 days up to 9 days of culture. Chondrocyte
aggregation was monitored using a Spot Insight QE digital
camera mounted on a Nikon eclipse TS100 inverted micro-
scope, and Spot Advanced version 3.5 imaging software. It
should be noted that histological examination of the collec-
tion sites from 4-day-old mice clearly demonstrate separable
growth plate and epiphyseal cartilage regions, but a distinct
articular population at the surface of the epiphysis was not
discernable. It is, however, possible that under the culture
conditions used (Opti-MEM etc.) some of the cells in these
cultures begin to express a more articular cell phenotype.
AGGRECAN SYNTHESIS AND DEGRADATION
Chondrocytes and media were aspirated from culture
wells and cells were pelleted in a Beckman Microfuge 12
at 1000 rfc for 5 min. The supernatant was removed and ad-
justed to 5 mM EDTA, 5 mM IAA, 0.1 mM AEBSF, 1 mg/ml
pepstatin, and 1 mg/ml leupeptin. Medium macromolecules
were precipitated with three volumes of 98% ethanol/
5 mM sodium acetate. The pelleted cell aggregates were
solubilized with 200 ml 4 M guanidine HCl, 50 mM sodium
acetate pH 6.8 (plus proteinase inhibitors as above) at
4(C for 16 h. Debris was removed by centrifugation and
macromolecules were precipitated with ethanol as above.
Desalted pellets from medium and cells were dissolved in
50 mM sodium acetate, 50 mM Tris, 10 mM EDTA, pH
7.6. S-GAG content was determined by DMMB31 and por-
tions (2e10 mg S-GAG) were taken for deglycosylation
and Western analysis as described27.
IMMUNOHISTOCHEMISTRY
At 3, 6 and 9 days, complete cell aggregates from one
well were pelleted by low-speed centrifugation (800 rfc;
Beckman Microfuge 12, 5 min), and ﬁxed in 10% phos-
phate-buffered formalin. Fixed pellets were encapsulated
in Histogel (Richard-Allan Scientiﬁc) before being pro-
cessed and embedded in Paraplast. Sections (4 mm) were
cut and mounted on Superfrost/Plus slides, which were
dried vertically for 1 h at room temperature and horizontally
for 18 h at 37(C. Sections were deparafﬁnized using stan-
dard procedures, rinsed in tap water for 5 min, incubated
in 10% neutral-buffered formalin for 30 min to improve tis-
sue adhesion, and ﬁnally washed for 5 min in tap water.
Sections were then treated with proteinase K (20 mg/ml)
for 20 min at 37(C, washed for 5 min at room temperature
with PBS containing 1 mM AEBSF, and incubated with ei-
ther JSCVMA (5.0 mg/ml), JSCKNG (1.0 mg/ml), JSCNIT
(0.2 mg/ml) or JSCTAS (1.0 mg/ml) in blocking serum as
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5 min and incubated with AlexaFluor568 goat anti-rabbit
IgG (1:250) for 1 h at room temperature and nuclei stained
for 10 min with TOTO-3 (T3604, Molecular Probes Inc., di-
luted 1:500 in PBS) and mounted with Vectashield mount-
ing medium (Vector Labs). To visualize the extracellular
matrix compartment, sections were also co-stained for hya-
luronan (HA) by an established method32. Brieﬂy, the G1
domain of bovine aggrecan was puriﬁed33, modiﬁed with
the EZ-link Sulfo-NHS-LC-biotinylation kit as described by
the supplier and used at 5.0 mg/ml bovine hyaluronan bind-
ing protein (bHABP). Sections were washed in PBS for
5 min and incubated with AlexaFluor488-streptavidin for
1 h at room temperature. To conﬁrm speciﬁcity of the immu-
nostains, sections were exposed to equivalent concentra-
tions of non-immune IgG, and for the bHABP stain,
sections were pretreated with Streptomyces hyaluronidase
(33TRU) in 50 mM sodium acetate buffer, pH 5.0, contain-
ing protease inhibitors, for 1 h at 37(C34. Stained sections
were examined using a Leica TCS SP2 Confocal scanning
Laser Microscope at a resolution of 1024 1024 pixels.
Results
AGGRECAN METABOLISM BY EPIPHYSEAL CHONDROCYTES
Murine epiphyseal chondrocytes formed multicellular as-
sociations [Fig. 1(A)] when cultured under non-adherentserum-free conditions23,24,35, and progressively aggregated
into larger clusters over 9 days. Histological evaluation of the
cultures [Fig. 1(B,C)] showed a progressive accumulation of
intercellular matrix, which was highly enriched in HA, partic-
ularly at day 6 [Fig. 1(C)]. Proteoglycan production (as-
sessed by S-GAG assay) remained essentially stable, at
about 40 mg of S-GAG per 3 days, over the 9 day period.
The majority of the S-GAG (~90%) was recovered in the me-
dium, and core protein analyses of these samples were done
with anti-G1, anti-G3, anti-NIT and anti-TAS. Media collected
at days 3, 6 and 9 contained variable amounts of the full-
length aggrecan core (species 1) along with the aggreca-
nase-generated species 5, 6, 7, 8, 9, 10 and 13 (see Fig. 3
for schematic of products and epitope locations). The propor-
tion of the aggrecan in fragmented form increased with time
in culture, as material released over the ﬁrst 3 days of culture
was largely intact (species 1) whereas that recovered at
days 6 and 9 contained mostly the degradation products
5e10 and 13. Veriﬁcation of the structural identity of the
core protein fragments was based on electrophoretic migra-
tion, multiple speciﬁc immunoreactivities and comparison
with the same species produced by aggrecanase activity in
rat36, bovine13 and human27 chondrocytes. For example, spe-
cies 1 shows speciﬁc reactivity with both anti-G1 [ Fig. 2(A)]
and anti-G3 [Fig. 2(B)], species 6 with both anti-G1
[Fig. 2(A)] and anti-NIT [Fig. 2(C)], and species 5 with both
anti-G1 [Fig. 2(A)] and anti-TAS [Fig. 2(D)]. On the otherDay 3 Day 6 Day 9
A
B
C
5 um
Fig. 1. Histological appearance of murine epiphyseal chondrocyte clusters at 3, 6 and 9 days in culture. (A) Phase contrast microscopy of live
cultures (25 magniﬁcation); (B) H&E stained thin sections of ﬁxed and parafﬁn embedded clusters (100 magniﬁcation). (C) Confocal local-
ization of HA (green) and nuclei (blue). It should be noted that the formalin ﬁxation and processing results in the detachment of some cells from
the lacuna wall and shrinkage onto the nucleus (blue). The localization of the cell body and plasmamembrane is not determined by this protocol.
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Fig. 2. Aggrecan species secreted into the medium by chondrocyte clusters from wild-type mice. Western blot analyses were performed with
media collected after 3, 6 and 9 days using anti-G1 (A), anti-G3 (B), anti-NIT (C) and anti-TAS (D). Electrophoretic migration of aggrecan spe-
cies (1, 5, 6, 7, 8, 9, 10 and 13, for structural identiﬁcation see Fig. 3) is indicated by arrowheads.hand, species 7, 8, 9 and 10 reacted only with anti-G3
[Fig. 2(B)] and species 13 only with anti-TAS [Fig. 2(D)].
To examine the kinetics of synthesis and degradation, to-
tal cultures (cells plus medium) were also terminated at 4, 8,
24, 36, 52, 60 and 72 h during the period of days 4e6, and
products were analyzed by Western blotting (Fig. 4). Scion
Image analyses of the staining intensity of immunoreactive
products at each time point showed that production of intact
aggrecan was detectable after 4 h post-medium change, itcontinued rapidly to reach a maximum at about 36 h, and
there was no further accumulation of the intact form up to
72 h. On the other hand, aggrecanase-mediated cleavage
to generate species 5,6,7,8,9,10 and 13 was minor in the
ﬁrst 24 h, it slowly increased up to 36 h and ﬁnally reached
a maximum between 52 and 60 h post-medium change. It is
therefore clear that high rates of synthesis and degradation
occur concomitantly in this culture system at 36e52 h, how-
ever, these two activities may be due to different cell1592
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Fig. 3. Schematic of aggrecan species detected in mouse chondrocyte cultures. The numbering scheme (1, 5, 6, 7, 8, 9, 10, 13) follows that
previously described for rat40, bovine13 and human27 aggrecan. The residue numbers shown in italics represent the respective terminal res-
idues (for example NVTEGE392) and are taken directly from the database for mouse aggrecan63 without adjustment in numbers for the leader
sequence.
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apart from most previous chondrocyte systems where in-
duction of catabolism by cytokines is accompanied by
a marked reduction in synthetic activity37.
IMMUNOHISTOCHEMICAL LOCALIZATION OF ADAMTS4,
ADAMTS5 AND AGGRECANASE PRODUCTS
Western analysis of conditioned media and cell extracts
for ADAMTS4 and ADAMTS5 were unsuccessful apparently
due to the low abundance of enzyme proteins. We make this
conclusion, since the analyses were done with antibodies
and conditions previously used successfully with bovine
and human chondrocytes and cartilage samples13,15. We
therefore examined the abundance of ADAMTS4 and
ADAMTS5 in cell clusters by immunohistochemistry with
highly sensitive ﬂuorescent probes at days 3, 6, 9 and 12.
Confocal immunostaining of ADAMTS5 (Fig. 5) showed
that at day 3 the signal was most intense around cells along
the surface, and also detectable around cells within the clus-
ters. Staining of ADAMTS5 within the clusters became more
pronounced by day 6, but was diminished by days 9 and 12.
ADAMTS4 staining (Fig. 5) was markedly less than the
staining of ADAMTS5, with only a few positive cells both
on the surface and within the cluster at day 3 and only
sparse surface staining at later stages (Fig. 5).Immunostaining for aggrecan degradation products with
anti-NIT and anti-TAS (Fig. 5) showed similarities in both
time-dependent appearance and spatial distribution of
both epitopes although TAS staining appeared more abun-
dant at all times. At day 3, staining for these components
was most intense in cell groups along the surface, with
weaker staining around cells inside the clusters. By compar-
ison, at day 6, staining for these neoepitopes intensiﬁed
both within the clusters and along the surfaces, and further-
more it became mostly concentrated within what appeared
to be cell lacunae.
To illustrate the temporal and spatial relationships be-
tween ADAMTS5 and the aggrecan degradation products,
the intercellular matrix compartment in these sections was
visualized by co-staining of HA (green) and images cap-
tured at higher magniﬁcation (Figs. 6 and 7). At all culture
times the degradation products (Fig. 7) were situated pri-
marily in pericellular locations, and distributed much like
the ADAMTS5 (Fig. 6). This apparent colocalization is con-
sistent with a primary role for ADAMTS5 in the generation of
these products. It is interesting that the general distribution
of HA (green) and proteins (red) appeared to be mutually
exclusive, suggesting that the products are not bound
to HA. Indeed image analyses (not shown) to examine co-
localization of aggrecan degradation products and HA indi-
cated that such associations were detectable in very few[1]
[5]
[6]
0 4 8 24 36 52 60 72
h post medium change
[5]
[13]
[1]
[10]
[9]
[8]
[7]
B
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C
Fig. 4. Kinetic analyses of aggrecan production and degradation in chondrocyte clusters from wild-type mice. Aggrecan species accumulated
in media plus cell layers at intervals indicated after medium change, were analyzed by Western blot using anti-G1 (panel A), anti-G3 (panel B)
and anti-TAS (panel C). Electrophoretic migration of aggrecan species (1, 5, 6, 7, 8, 9, 10 and 13) is indicated by arrowheads. Structures of the
aggrecan species are given in Fig. 3.
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Fig. 5. Confocal immunolocalization of ADAMTS4, ADAMTS5 and aggrecanase-generated neoepitopes (NIT and TAS) in chondrocyte clus-
ters. Cell clusters were processed for immunohistochemistry and confocal imaging as described in Methods section. Cross-sectional images
of representative specimens after 3, 6, 9 and 12 days are shown. Protein epitopes (see respective antibody description at bottom) were
visualized by AlexaFluor-conjugated secondary antibody (red) and nuclei counterstained blue with TOTO-3.locations in the intercellular and pericellular matrix. This
would indicate that in this culture system the G1-bearing ag-
grecanase products are generated within the HA-poor peri-
cellular space (also see Fig. 1), and released into the
medium without detectable association with the HA-rich
intercellular matrix.
We have not attempted quantitation of the ADAMTS ﬂuo-
rescent signals in this study since the marked changes in
intensity and distribution (Fig. 5) were consistently observed
in three consecutive sections through the clusters. In addi-
tion the signal intensity changes for all epitopes were also
observed with DAB staining of nine consecutive sections
showing that the DAB and ﬂuorescent methods of detection
were in good agreement. It is signiﬁcant that the abundance
of the ﬂuorescent signals for TAS and NIT (Fig. 5) was con-
sistent with the abundance of these products shown by
Western analysis (Fig. 2).
AGGRECAN SYNTHESIS AND DEGRADATION BY
CHONDROCYTES FROM MUTANT MICE
Chondrocytes from mice bearing null mutations in puta-
tive aggrecanase cascade members16 were also examinedin this culture model. Products formed by cells derived from
CD44-null [Fig. 8(A)], syndecan-1-null [Fig. 8(B)] and
MT4MMP-null mice (data not shown) were probed with
anti-G1 and also characterized (not shown) by reactivity
with multiple antibodies as shown above for the wild-type
cells. The results demonstrated that essentially wild-type
rates of aggrecan synthesis and aggrecanase-mediated
cleavage patterns occurred with these cells, indicating that
none of these three components are essential for aggreca-
nolysis by murine chondrocytes under these conditions. In
marked contrast, cells from ADAMTS5-null mice produced
normal amounts of aggrecan but were essentially unable
to degrade the aggrecan by an aggrecanase-mediated
pathway [Fig. 8(C)] or apparently by any other pathway.
This resulted in the release of species 1 with no evidence
for any of the previously described aggrecanase-generated
species 6, 7, 8, 9, 10 and 13. The detection of trace
amounts of species 5 in these samples has not been further
investigated. In addition, cell layer aggrecan recovered from
the ADAMTS5-null cultures contained only species 1 (data
not shown), consistent with essentially complete elimination
of aggrecanolysis by ablation of the ADAMTS5 catalytic do-
main. Cells from the wild-type litters of all mutant strains
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Fig. 6. Localization of ADAMTS4, ADAMTS5 and HA in chondrocyte clusters. Cell clusters were processed for immunohistochemistry and
confocal imaging as described in Methods section. Cross-sectional images of representative specimens after 3, 6 and 9 days. Protein epitopes
are shown in red, HA in green and nuclei in blue.generated aggrecanolysis products essentially identical to
that shown (Fig. 2) for the wild-type C57BL/6J strain used
in the majority of studies reported here.
Discussion
The murine chondrocyte culture system described here
achieves aggrecan synthesis at a rate which is similar to
that previously described for serum-containing cultures of
rabbit and bovine epiphyseal chondrocytes38 and rat chon-
drosarcoma cells39. This provides sufﬁcient product for par-
allel biochemical and immunohistochemical studies of the
aggrecan degradation pathways, and to examine the effect
of gene manipulation on speciﬁc aspects of the process.
The culture conditions used (non-adherent, Opti-MEM)
provided both a high rate of biosynthesis in the absence of
serum and a high rate of aggrecanolysis without the addi-
tion of exogenous catabolic stimulators. In previously stud-
ied chondrocyte cultures40 and cartilage explants13,14,19,20
newly synthesized aggrecan is deposited in the matrixand the aggrecanase process is initiated through catabolic
stimulants such as IL-141, TNFa and oncostatin M
(OSM)18 retinoic acid 12, lipopolysaccharide (LPS)42, ﬁbro-
nectin fragments (FnF)43, TGFbeta44,45, IL-1746,47, thyroid
hormone48 or neprilysin 49. The spontaneous degradation
seen in the present culture might be related to the ﬁnding
that the pericellular aggregate assembly process is appar-
ently inefﬁcient, since only a small proportion of newly syn-
thesized intact aggrecan deposited in the cell-associated
matrix, with >90% released into the medium at all culture
times. Histological analyses of the cell clusters [Fig. 1(C)]
showed the presence of abundant ‘free’ HA in the intercel-
lular matrix indicating that poor deposition of aggrecan was
not due to limiting HA but possibly due to a deﬁciency in link
protein production in the absence of serum7, or a low HA
binding-afﬁnity of the newly synthesized aggrecan50.
When taken together, these ﬁndings indicate that degrada-
tion of a major proportion of the newly synthesized aggre-
can (up to 50%) occurs very soon after secretion of
monomer, and that inefﬁcient assembly of link-stabilized ag-
gregates7 may result in enhanced degradation of this
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Fig. 7. Localization of aggrecanase-generated neoepitopes (TAS and NIT) and HA in chondrocyte clusters. Cell clusters were processed for
immunohistochemistry and confocal imaging as described in Methods section. Cross-sectional images of representative specimens after 3, 6
and 9 days. Protein epitopes are shown in red, HA in green and nuclei in blue.population. In support of this interpretation, confocal locali-
zation of the ADAMTS5 protein (Figs. 5 and 6) showed it
to be the most abundant in the immediate pericellular
space, in a distribution pattern similar to both degradation
products. In contrast, the HA was the most abundant in
the intercellular regions. It is of interest to note that the pres-
ent culture system has several features in common with
chondrogenic micromass cultures51e53, which generate
HA-rich ‘cartilagenous’ nodules54 and which stain positive
for extracellular matrix, including alcian blue-positive glyco-
saminoglycans, aggrecan, versican and collagen II by im-
munohistochemistry. The present data open the question
of whether cells in such ‘‘chondrogenic’’ culture systems
use the same pathway for aggrecanolysis as the epiphyseal
cells described here. Manipulation of this process by inter-
ference with the catabolic events could open new avenues
for study of de novo chondrogenesis for tissue engineering
applications.
In conclusion, the use of cells from genetically modiﬁed
mice clearly provides a new avenue for investigation ofnormal and pathological processes related to chondrocyte
function55. Studies in cartilage matrix biology, endochondral
ossiﬁcation and skeletal tissue repair can now be addressed
with this and related culture systems. For example, chondro-
cytes from mice lacking transglutaminase56,57, Runx2/
Cbfal58, cyclic GMP-dependent protein kinase II59, HIF-
1a60 and beta1-integrin61 have all been used to illuminate
the precise effect of the genetic defect on chondrocyte-au-
tonomous activities. In this regard our results (Fig. 8) con-
ﬁrmed that ADAMTS5 is primarily responsible for
aggrecanolysis by mouse chondrocytes, consistent with re-
cent reports with IL-1-treated 3e4-week-old femoral head
cartilage explants from these mutant mice19,20. On the other
hand, murine strains null for MT4MMP, syndecan-1 or the
HA receptor CD44 displayed normal aggrecanase-mediated
cleavages. This indicates that these components, previously
shown or suggested to support ADAMTS4-mediated aggre-
canolysis in bovine or human chondrocytes13,15,16,62 are not
required in the ADAMTS5-mediated murine aggrecanase
cascade. In this regard it is also interesting to note that the
400 M. C. Stewart et al.: Aggrecanase in murine chondrocytes[1]
[5]
[6]
CD44(-/-) Syndecan-1(-/-) ADAMTS5(-/-)
day3 day6 day9 day3 day6 day9 day3 day6 day9
Fig. 8. Aggrecan degradation in chondrocyte clusters from CD44-null mice, syndecan-1-null mice and ADAMTS5-null mice. Aggrecan species
collected from the medium at days 3, 6 and 9 were identiﬁed by Western blot analyses using anti-G1. Electrophoretic migration of aggrecan
species (1, 5 and 6) is indicated by arrowheads, and structures of the aggrecan species are given in Fig. 3. Analyses of cell layer products (not
shown) were essentially identical to the medium analyses.cells used in the present work produce detectable m-RNA
for all six aggrecanases (data not shown). The control mech-
anisms for selection of a speciﬁc aggrecanase to degrade
aggrecan, in this situation ADAMTS5, are clearly complex
and perhaps this culture system offers potential for investi-
gations into this question. Indeed, more work is required to
determine whether ADAMTS5 is the enzyme primarily re-
sponsible for normal and pathological turnover of aggrecan
in other species, and particularly in human arthritic diseases.
We expect progress toward this goal when human chondro-
cytes taken from arthritic cartilages are analyzed by confocal
immunolocalization in the culture system described here.
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